Celyad Oncology SA (ENXTBR:CYAD) announced that it is conducting a comprehensive review of strategic alternatives. Given the Company?s current financial position and the general state of biotech market, this review now includes potential asset sales, operational and organizational restructuring, and possible mergers or business combination, in addition to potential financing from the public or private sale of equity, debt financings or funds from other capital sources, partnerships, and licensing of assets that the Company has been evaluating. The evaluation is ongoing, and Celyad emphasized that no decisions have been made at this time.
The Company?s goal is to identify the best path to strengthen its balance sheet and maximize value for shareholders. There can be no assurance that this process will result in the Company pursuing a transaction or any other strategic outcome. As of December 31, 2024, Celyad reported a treasury position of ?4.2 million.
Management reiterates that existing cash will fund operations only into the third quarter of 2025. In light of this limited cash runway, the Board of Directors of Celyad noted that additional financing or a strategic transaction will likely be needed to support continuing operations. Celyad has already initiated refinancing discussions with investors and advisors to address its funding needs.
Matt Kane, Chief Executive Officer of Celyad, commented: ?The Board is now exploring multiple strategic alternatives. Potential options include forming collaborations or co-development partnerships, licensing or selling select technology platforms, merging with a complementary company, and reorganizing internal operations to further reduce expenses. Celyad has already taken steps towards some of these goals: the Company is currently in discussion with potential partners for out-licensing deals on its CAR-T and shRNA platforms.?
Celyad reiterated this process is exploratory, and no final determinations have been made.
